From:
s 9(2)(a)
To:
s 9(2)(a)
Cc:
s 9(2)(a)
Subject:
COVID-19 vaccine consult feedback email to Medsafe
Date:
Monday, 11 August 2025 1:06:00 pm
Attachments:
image002.png
2025-06 COVID-19 consult response themes for Medsafe.xlsx
Hi s 9(2)(a)
I am writing to pass on some feedback that was provided to Pharmac through the public
consultation on the Proposal to award Principal Supply for the COVID-19 vaccine.
Please find attached a copy of the feedback forms spreadsheet. You are able to use the
filters to look at the different themes. Be sure to highlight each theme from Theme 1-6
separately to see all feedback that relate to that theme due to how the tagging was
completed.
There were a few themes that came out of this feedback that could be of interest to
Medsafe that are outlined below:
We received feedback from consumers around safety concerns of COVID-19
vaccines as well as mRNA vaccine technology.
There was feedback around the eligibility criteria for the COVID-19 vaccine with
some questioning the suitability and expressing concerns over safety for pregnant
women and healthy people aged 18 years and under.
There was also feedback that included adjusting the booster frequency from every 6
to every 12 months.
Consumers also provided feedback on the protection offered by the vaccine against
COVID-19, and whether the vaccine provides sufficient protection against the newer
strains.
We are in the process of preparing the COVID-19 vaccine decision notification and will
under the Official Information Act 1982
share a draft copy of this with you prior to sending this out.
Ngā mihi,
ed
s 9(2)(a)
s 9(2)(a)
| Therapeutic Group Manager
_____________________________________________________
PHARMAC | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington
ReleaDDI: +64 s 9(2)(b)(ii) | P: +64 s 9(2)(b)(ii) | www.pharmac.govt.nz
The information contained in this email (including any attachments) is private and confidential and may be legally privileged. It may
only be used for the purpose for which it has been provided. This email may contain patient information and is thus subject to the
Excerpts in this document have been released in accordance with section 16(1)(e) of the Act, with information
deemed out of scope of your request excluded.
Extract of Memorandum for Board Meeting - 29 July 2025
under the Official Information Act 1982
Released
